


# Uniting the Private Sector to Stop TB

The Private Sector Constituency of the Stop TB Partnership Membership Brochure



PRIVATE  
SECTOR  
CONSTITUENCY

Stop TB Partnership

# THE UNIFIED VOICE of the Private Sector to the Stop TB Partnership

The Private Sector Constituency (PSC) is a diverse set of businesses that, together, represent the private sector to the Stop TB Partnership.

The PSC supports the global TB community's vision and commitment of achieving a world free of TB by 2030, as seen in the 2018 Political Declaration of the United Nations on the Fight Against Tuberculosis.


**PRIVATE SECTOR CONSTITUENCY**  
Stop TB Partnership

The PSC is leveraging its members' knowledge and resources in service of a tuberculosis-free world. Through individual and collective action, awareness-raising and, shaping global strategies, PSC members provide unique perspectives to the Stop TB Partnership.

## WHY TUBERCULOSIS



Tuberculosis (TB) is the world's most deadly infectious disease.<sup>1</sup>



In 2018, more than **10 million** people fell ill with TB, of which **1 ½ million** died of the disease.



>



+



Globally, TB causes more deaths than malaria and HIV/AIDS combined.



TB costs over \$21 billion to the global economy annually.<sup>2</sup>

In 2018, TB was RESPONSIBLE FOR:

<b>\$1 BILLION</b> LOST PRODUCTIVITY from wage earners too sick to work	<b>\$11 BILLION</b> FROM DEATHS CAUSED BY TB, with an average loss of 15 years' income	<b>\$9.2 BILLION</b> GLOBAL COST of caring for TB patients
---	---	---

<sup>1</sup> United Nations General Assembly, Resolution A/RES/73/3 on the Fight Against Tuberculosis, 26 September 2018.

<sup>2</sup> Stop TB Partnership, "Global Report on Tuberculosis Vaccines 2018", <http://bit.ly/2QBoyja>.




## DRUG-RESISTANT TUBERCULOSIS

Drug-resistant tuberculosis (DR-TB) affects more than half a million people across the globe annually, and even with treatment, only about half of people who contract the disease are cured.

Drug-resistant TB (DR-TB) is the only major airborne drug-resistant epidemic, and it is predicted that DR-TB will cost the global economy approximately US\$17 trillion by 2050 if it remains unchecked.

Because of its resistance to drugs, tuberculosis poses a major threat to global health security. Multidrug-resistant tuberculosis (MDR-TB) is TB that does not respond to isoniazid and rifampicin, the two most powerful anti-TB drugs.

In 2017  
an estimated  
**558,000**  
PEOPLE WORLDWIDE  
DEVELOPED MDR-TB



Around **6.2%**  
of MDR-TB cases have extensively  
**DRUG-RESISTANT TUBERCULOSIS**  
(XDR-TB), a form of TB which is  
resistant to at least four of the core  
anti-TB drugs.



DEATHS ATTRIBUTABLE TO ANTIMICROBIAL RESISTANCE could rise to 10 million annually by 2050, with **2.5 million** of those deaths caused by drug-resistant tuberculosis.<sup>3</sup>

<sup>3</sup> World Health Organization. Global Tuberculosis Report 2019. October 2019. <http://bit.ly/366cVYa>.

# THE STIGMA

associated with TB remains high, creating barriers to accessing care and treatment.

## COMMON **MYTHS** ABOUT TB


Common misconceptions include that

People with TB...

...cannot live a **NORMAL LIFE** again



...are **CONTAGIOUS FOREVER**



...can't **STUDY OR WORK** during treatment



“

Initially I did face self-stigma and tried to stay isolated. The biggest challenge for me was the duration of the treatment and the side effects of the medicines, especially the mental ones. But I was lucky that my family, colleagues and employer were very supportive—my workload was reduced for me to avoid stress and my work hours were flexible to allow me to visit the doctor whenever I needed to.”

Himanshu Patel, a TB survivor

# TUBERCULOSIS CAN BE EVERY BUSINESS' BUSINESS

The PSC affords members a unique and diverse community of companies who are interested in joining forces to collaborate on projects and initiatives that can advance the global TB agenda by making TB every business' business.

Membership with the PSC unlocks a wide range of opportunities to elevate individual and collective actions of its members by:



## Making the case for private sector's engagement through shared goals & strategic priorities

Engaging the private sector is critical to addressing TB in the highest burden countries. That is why the PSC priorities revolve around three main workstreams, enabling its members to unite around common goals and to speak with one voice.

Through active member participation and careful consideration of stakeholder needs and expectations, the PSC has organized around **three strategic priorities** to guide near and midterm contributions, including:



### TB Advocacy & Communication

PSC members are elevating TB on the global political agenda through coordinated advocacy efforts, and are exploring new engagement models to spread awareness and mobilize resources.



### Data & Diagnostics

PSC members are fighting for better prevention using cutting-edge data and diagnostic tools, by enhancing and streamlining data generation and use through integration of existing technologies and cultivating new partnerships.



## Improving collaboration between the public and private sectors, and shaping global strategies by actively engaging and contributing unique perspectives in the Stop TB Partnership

The PSC is the official voice of the private sector at the Stop TB Partnership's events and meetings, including the Stop TB Partnership Board, and also represents its members at major global and regional events such as the annual Union World Conference on Lung Health, the World Health Organization's World Health Assembly, and others.

The PSC offers the opportunity to its members to access a growing global TB community by facilitating introductions with stakeholders-of-interest, ranging from NGOs to civil society, international organizations and country-level experts.

With ambitious targets set by the UN General Assembly's call to action in 2018, one of the PSC's main priority is to maintain strong relationships between its member companies and PSC partners in the public sector.

This is why in addition to attending meetings and events, PSC members continuously help shape the TB global conversation by:

- Providing consultative input on policy documents from the Stop TB Partnership
- Developing policy positions and guidelines
- Conducting Advocacy Campaigns to keep elevating TB on the global health agenda
- Creating and promoting unique private sector-led initiatives like the healthy workplaces project



## Learning and sharing with a vast and diverse network of companies

As a coalition, PSC members regularly meet internally to discuss the PSC strategy and ongoing TB efforts. Members have access to teleconferences, in-person PSC retreats, and to group communications through which they can learn about ongoing company initiatives, discuss prospective group engagements, and help shape the workstream's strategic priorities.

The PSC provides members with a unique platform to share and learn from each other. Members regularly share their experiences leading successful public-private partnerships, launching in-house TB initiatives and navigating the global health agenda, with the support of the PSC Secretariat.



## Become a member of the PSC

PSC members include healthcare organizations, pharmaceutical companies and medical equipment suppliers, but also representatives from the gas and mining industries, management consultancies, and manufacturing and construction sectors.

We are greater than the sum of our parts. By collaborating with each other and coordinating our efforts, we can finally eradicate this 17,000-year-old disease, build opportunity around the world, and improve world economies – and millions of lives.



### Membership Levels

AFFILIATE	FULL MEMBER All the Affiliate's services plus:	GOVERNANCE COUNCIL All Full Member services plus:
Company name on the Stop TB website	Early access to event invitations	Access to meetings with Stop TB Partnership leadership
Quarterly newsletter	Board prep calls	Voting rights on overall PSC strategy
Quarterly calls	Ad-hoc initiative calls	Automatic membership of the
Invitation to side events	Profiling opportunities in the PSC best practice book	Governance Task Force
	Policy insights	5 hours of 1:1 consulting on issue of choice
	Workstream participation	Sponsorship opportunities for event
	Eligibility for workstream leadership	Agenda setting for events
	Eligibility to sit on panels	Access to ad-hoc caucuses with other Stop TB constituencies alongside official events
	Voting rights for Chair election	
	Exclusive to Tier 2B: Participation in the "PSC Mileage Program"	

**Join us to put an end to the TB epidemic!**

Contact the Secretariat of the Private Sector Constituency to the Stop TB Partnership to learn more about our membership fees and ongoing projects by contacting **Mario Ottiglio** at [mottiglio@highlanterngroup.com](mailto:mottiglio@highlanterngroup.com)



© PAHO

**PRIVATE  
SECTOR  
CONSTITUENCY**  
**Stop TB Partnership**

**Secretariat of the Private Sector Constituency  
to the Stop TB Partnership**

Campus Biotech. Innovation Park  
Av. de Sécheron 15. 1201 Geneva  
Switzerland